STTR Phase I: Sensor Probe for Monitoring Li+ in Bipolar Patients Subscribed to Lithium Therapy

STTR 第一阶段：用于监测接受锂治疗的双相情感障碍患者锂的传感器探针

• 批准号: 9903642
• 负责人: Kevin Morris
• 金额: $ 9.99万
• 依托单位: Critical Angle, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2000-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9903642&HistoricalAwards=false
• 关键词: STTR; Phase; Sensor; Probe; Monitoring

This Small Business Technology Transfer (STTR) Phase I project aims to develop a miniaturized biosensor for rapid in vivo determination of Li+ in human body fluids. The biosensor will be based upon complexation between three independent surface bound crown ethers which will be able to identify and ratio Li+ ions against the common interferant ions Na+, or K+. Coordination of the ion/s will be detected by Surface Plasmon Resonance Spectroscopy. This project will consist of a series of experiments which, if successful, will allow development of a miniaturized user-friendly, fiber-optic probe to detect a positively charged ion (cation, e.g. Li+) in low concentrations in body fluids. Logical progression will comprise adapting an existing SPRS surface modification technology to the tethering of the ion selective crown ethers for Li+, Na+ and K+. This project will include the synthesis and purification of the crown, 4-aminobenzo-12-crown-4 as this compound is not available commercially. Further, the chemically modified surfaces will be examined for selectivity against each individual ion and in the presence of a mixture of all three. Finally, the limits of detection will be addressed. A completed miniaturized portable device based on this proposed research will rapidly and reliably detect ionic concentrations/imbalances in human or biological subjects. This device will monitor lithium (Li+) in known bipolar disorder patients under lithium therapy. In situ rapid detection will minimize clinical laboratory time, increase the "safety net' against over-medicating, and provide the patient/doctor with instant feedback to determine appropriate dosage.

该小型企业技术转让（STTR）第一阶段项目旨在开发一种微型生物传感器，用于快速体内测定人体体液中的Li+。 该生物传感器将基于三个独立的表面结合的冠醚之间的络合作用，其将能够识别Li+离子并将Li+离子与常见的干扰离子Na+或K+进行比率。 将通过表面等离子体共振光谱法检测离子的配位。该项目将包括一系列实验，如果成功，将允许开发一种小型化的用户友好的光纤探针，以检测体液中低浓度的带正电荷的离子（阳离子，如Li+）。合理的进展将包括使现有的SPRS表面改性技术适应于Li+、Na+和K+的离子选择性冠醚的束缚。该项目将包括合成和纯化冠醚4-氨基苯并-12-冠-4，因为这种化合物没有商业供应。 此外，将在所有三种离子的混合物存在下检查化学改性表面对每种离子的选择性。 最后，将讨论检测极限。 一个完整的小型便携式设备的基础上提出的这项研究将迅速和可靠地检测离子浓度/不平衡的人或生物受试者。该器械将监测接受锂治疗的已知双相情感障碍患者的锂（Li+）。 原位快速检测将最大限度地减少临床实验室时间，增加防止过度用药的“安全网”，并为患者/医生提供即时反馈以确定适当的剂量。